Ramsey Cheung
YOU?
Author Swipe
View article: High Prevalence of Cirrhosis or Hepatocellular Carcinoma at Hepatitis Delta Infection Diagnosis Reflects Alarming Delays in Testing
High Prevalence of Cirrhosis or Hepatocellular Carcinoma at Hepatitis Delta Infection Diagnosis Reflects Alarming Delays in Testing Open
Delays in timely diagnosis and treatment of hepatitis delta virus (HDV) contribute to more severe liver disease at presentation. We aim to evaluate the prevalence and predictors of advanced liver disease at presentation among a national co…
View article: Delayed Diagnosis of Hepatitis C Infection: Results of a Nationwide US Study
Delayed Diagnosis of Hepatitis C Infection: Results of a Nationwide US Study Open
Introduction: Universal screening of hepatitis C virus (HCV) was encouraged for individuals born 1945–65 in the USA in 2012. In 2014, efficacious treatments, namely, direct-acting antivirals (DAAs), were introduced. To examine their impact…
View article: Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study Open
None.
View article: Sex Differences in Risk of Adverse Liver Events in Patients With Cirrhosis
Sex Differences in Risk of Adverse Liver Events in Patients With Cirrhosis Open
Importance Patients with cirrhosis are at high risk of developing adverse liver events. However, data on sex differences are limited. Objective To compare risk of adverse liver events between male and female patients with cirrhosis. Design…
View article: Peri-Complication Diagnosis of Nonalcoholic Fatty Liver Disease: A US Population-Based Retrospective Analysis
Peri-Complication Diagnosis of Nonalcoholic Fatty Liver Disease: A US Population-Based Retrospective Analysis Open
Introduction: Screening guidelines for nonalcoholic fatty liver disease, now called metabolic dysfunction‐associated steatotic liver disease (MASLD), remain controversial, though early diagnosis can faciliate intervention and prevention. M…
View article: Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests
Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests Open
Our study assessed the cost-effectiveness of screening for hepatic fibrosis in cases suspected of metabolic dysfunction-associated steatotic liver disease (MASLD) using serological noninvasive tests like the fatty liver index (FLI) and hep…
View article: Projected Trends in Metabolic Dysfunction–Associated Steatotic Liver Disease Mortality Through 2040
Projected Trends in Metabolic Dysfunction–Associated Steatotic Liver Disease Mortality Through 2040 Open
Importance Population-based data for metabolic dysfunction–associated steatotic liver disease (MASLD)–related mortality trends and forecasts in the United States are limited. Objective To examine MASLD-related mortality trends in the Unite…
View article: Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up
Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up Open
Screening for metabolic dysfunction-associated steatotic liver disease (MASLD) across the entire general population is not currently a recommended strategy. However, it is not uncommon to receive a medical check-up or health check-up for a…
View article: Projected Tumor Characteristics and Survival of Patients with Nonviral Hepatocellular Carcinoma in the USA
Projected Tumor Characteristics and Survival of Patients with Nonviral Hepatocellular Carcinoma in the USA Open
Introduction: Nonviral liver diseases, including alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), are increasing the burden of nonviral hepatocellular carcinoma (HCC) in the USA. …
View article: Late Diagnosis of Chronic Hepatitis B in the United States: A Population‐Based, Retrospective Cohort Study From 2007 to 2021
Late Diagnosis of Chronic Hepatitis B in the United States: A Population‐Based, Retrospective Cohort Study From 2007 to 2021 Open
Background Underdiagnosis of chronic hepatitis B (CHB) remains a major problem in the United States (USA), with > 80% of CHB patients remaining undiagnosed. Aims To determine the prevalence of late diagnosis of CHB and resultant liver comp…
View article: Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study
Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study Open
Background/Aims: Information about the association of glucagon-like peptide-1 receptor (GLP-1RA) with liver and non-liver complications is insufficient in patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic l…
View article: Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues
Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues Open
Background/Aims: Given the increase in prevalence of metabolic diseases, we investigated their long-term impacts on the outcomes of chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogue (NA) treatment.Methods: We analyzed dat…
View article: Secondary Spontaneous Bacterial Peritonitis Prophylaxis Is Associated With a Higher Rate of Infections other than Spontaneous Bacterial Peritonitis in 2 US-Based National Cirrhosis Cohorts
Secondary Spontaneous Bacterial Peritonitis Prophylaxis Is Associated With a Higher Rate of Infections other than Spontaneous Bacterial Peritonitis in 2 US-Based National Cirrhosis Cohorts Open
INTRODUCTION: Antibiotic overuse and subsequent antibiotic resistance lead to worse infection outcomes in cirrhosis. Secondary spontaneous bacterial peritonitis prophylaxis (SecSBBPr) is associated with higher SBP recurrence, but impact on…
View article: Supplementary Table 2 from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors
Supplementary Table 2 from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors Open
Supplementary Table 2 shows the results from the adjusted multivariable logistic regression analyses evaluating for predictors of receipt of HCC treatment, stratified by race/ethnicity.
View article: Supplementary Table 1 from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors
Supplementary Table 1 from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors Open
Supplementary Table 1 shows the results of adjusted multivariable logistic regression analyses evaluating for predictors of tumor stage at diagnosis among patients with HCC, stratified by race/ethnicity.
View article: Data from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors
Data from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors Open
Background:Hepatocellular carcinoma (HCC) disproportionately affects racial/ethnic minorities. We evaluated the impact of income and geography on racial/ethnic disparities across the HCC care cascade in the United States.Methods:Using NCI …
View article: Supplementary Table 7 from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors
Supplementary Table 7 from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors Open
Supplementary Table 7 shows results from the adjusted multivariable competing risks analyses evaluating for predictors of HCC-specific mortality, stratified by race/ethnicity.
View article: Supplementary Table 5 from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors
Supplementary Table 5 from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors Open
Supplementary Table 5 shows results from the adjusted multivariable Cox proportional hazards model evaluating for predictors of overall mortality, stratified by race/ethnicity
View article: Supplementary Table 4 from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors
Supplementary Table 4 from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors Open
Supplementary Table 4 shows the results from the adjusted multivariable logistic regression analyses evaluating for predictors of delays in HCC treatment (≥3 months vs.
View article: Supplementary Table 3 from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors
Supplementary Table 3 from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors Open
Supplementary Table 3 shows results from the adjusted multivariable logistic regression analyses evaluating for predictors of receiving HCC surgical treatment, stratified by race/ethnicity.
View article: Supplementary Table 6 from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors
Supplementary Table 6 from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors Open
Supplementary Table 6 shows results from the adjusted multivariable competing risks analyses evaluating for predictors of hepatocellular carcinoma-specific mortality.
View article: Supplementary Figure 1A-E from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors
Supplementary Figure 1A-E from Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors Open
Supplementary figure 1A shows the overall 5-year survival of patients with HCC stratified by age groups. Supplementary figure 1B shows the overall 5-year survival of patients with HCC stratified by sex. Supplementary figure 1C shows the ov…
View article: Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors
Significant Disparities in Hepatocellular Carcinoma Outcomes by Race/Ethnicity and Sociodemographic Factors Open
Background: Hepatocellular carcinoma (HCC) disproportionately affects racial/ethnic minorities. We evaluated the impact of income and geography on racial/ethnic disparities across the HCC care cascade in the United States. Methods: Using N…
View article: Sex Differences in Adverse Liver and Nonliver Outcomes in Steatotic Liver Disease
Sex Differences in Adverse Liver and Nonliver Outcomes in Steatotic Liver Disease Open
This cohort study examines the association of sex with liver and nonliver adverse events using data from a US nationwide population-based database of patients with metabolic dysfunction–associated steatotic liver disease.
View article: Demographic and clinical characteristics associated with utilization of alcohol use disorder treatment in a multicenter study of patients with alcohol‐associated cirrhosis
Demographic and clinical characteristics associated with utilization of alcohol use disorder treatment in a multicenter study of patients with alcohol‐associated cirrhosis Open
Background Alcohol use disorder (AUD) treatment can help improve clinical outcomes among patients with alcohol‐associated cirrhosis but is underutilized. Among socioeconomically disadvantaged patients with alcohol‐associated cirrhosis, we …